Evaluation of Biochemical Conditions Allowing Bypass of Confirmatory Testing in The Workup of Primary Aldosteronism: A Retrospective Study in a French Hypertensive Population

Abstract

The diagnostic workup for primary aldosteronism includes a screening step using the aldosterone-to-renin ratio (ARR) and a confirmatory step based on dynamic testing of aldosterone secretion autonomy. International guidelines suggest that precise clinical and biochemical conditions may allow the bypassing of the confirmatory step, however, data which validate hormone thresholds defining such conditions are lacking. At our tertiary center, we retrospectively examined a cohort of 173 hypertensive patients screened for PA by the ARR, of whom 120 had positive screening and passed a saline infusion test (SIT) or a captopril challenge test (CCT). Fifty-nine had PA, including 34 Conn adenomas and 25 with idiopathic aldosteronism (IA). Using a threshold of 160 pmol/l, post-SIT plasma aldosterone concentration (PAC) identified PA with 86.4% sensitivity, 94.7% specificity, and a negative predictive value of 92.3%. Of those subjects with a high ARR and a PAC above 550 pmol/l, 93% had a positive SIT, while 100% of subjects with a high ARR, but a PAC under 240 pmol/l had a negative SIT. Our results thus validate the biochemical conditions defined in the French and US guidelines for bypassing the confirmatory step in the workup for PA diagnosis.

Key words

adrenal - hypertension - primary aldosteronism - confirmatory test

• References

• 1 Fardella CE, Mosso L, Gomez-Sanchez C. et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
• 2 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 3 Mulatero P, Stowasser M, Loh KC. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
• 4 Hannemann A, Bidlingmaier M, Friedrich N. et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7-15
• 5 Douma S, Petidis K, Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926
• 6 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 7 Douillard C, Houillier P, Nussberger J. et al. SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. Ann Endocrinol (Paris) 2016; 77: 192-201
• 8 Nishikawa T, Omura M, Satoh F. et al. Guidelines for the diagnosis and treatment of primary aldosteronism–the Japan Endocrine Society. 2009; Endocr J 2011; 58: 711-721
• 9 Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing. Ann Endocrinol (Paris) 2016; 77: 202-207
• 10 Mulatero P, Milan A, Fallo F. et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2618-2623
• 11 Rossi GP, Belfiore A, Bernini G. et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007; 25: 1433-1442
• 12 Giacchetti G, Ronconi V, Lucarelli G. et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24: 737-745
• 13 Ahmed AH, Cowley D, Wolley M. et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99: 2745-2753
• 14 Li Y, Liu Y, Li J. et al. Sodium infusion test for diagnosis of primary aldosteronism in chinese population. J Clin Endocrinol Metab 2016; 101: 89-95
• 15 Meng X, Li Y, Wang X. et al. Evaluation of the saline infusion test and the captopril challenge test in chinese patients with primary aldosteronism. J Clin Endocrinol Metab 2018; 103: 853-860
• 16 Song Y, Yang S, He W. et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension 2018; 71: 118-124
• 17 Agharazii M, Douville P, Grose JH. et al. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440-1443
• 18 Willenberg HS, Vonend O, Schott M. et al. Comparison of the saline infusion test and the fludrocortisone suppression test for the diagnosis of primary aldosteronism. Horm Metab Res 2012; 44: 527-532
• 19 Nanba K, Tamanaha T, Nakao K. et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 2012; 97: 1688-1694
• 20 Morera J, Reznik Y. Management of Endocrine Disease: The role of confirmatory tests in the diagnosis of primary aldosteronism. Eur J Endocrinol 2018; pii EJE-18-0704.R2 DOI: 10.1530/EJE-18-0704.
• 21 Letavernier E, Peyrard S, Amar L. et al. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008; 26: 1816-1823
• 22 Mosso L, Carvajal C, Gonzalez A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165